毕得医药：股东合计减持1.12%股份，持股降至10%

Core Viewpoint - Bid Pharma announced a share reduction by major shareholders, which will not significantly impact the company's governance or operations [1] Group 1: Shareholder Actions - From November 13 to December 19, 2025, shareholders Zhoushan Landan Enterprise Management Partnership (Limited Partnership) and its concerted action person Wu Bo, along with Zhoushan Xinxin Enterprise Management Partnership (Limited Partnership), collectively reduced their holdings by 1,022,400 shares, accounting for 1.12% of the total share capital [1] - Following this equity change, the combined shareholding ratio of the three parties decreased from 11.12% to 10%, reaching a 5% integer threshold [1] - The reduction is part of a previously planned action and does not trigger a mandatory takeover bid [1]